Thematic Exposure -- 7/10
Novo Nordisk is one of two players in a global GLP-1 duopoly riding the single best secular theme in
pharma -- obesity and cardiometabolic disease. The position clears the oligopoly hard gate: Novo and
Lilly together control ~98% of GLP-1 obesity, and Novo holds >30% share across obesity GLP-1
(~40-47%), GLP-1 diabetes (~46%), insulin (~45%), and total diabetes (~30%). But Novo is the #2 player
and is actively ceding share to Eli Lilly in the fastest-growing piece -- exactly the "don't settle for
#2" warning -- which is what keeps this off a 9-10.
Weight: 35%
Obesity / GLP-1 -- Best Secular Theme in Pharma
Secular Tailwind -- Multi-Year Visibility
Obesity/cardiometabolic is the strongest growth theme in healthcare (~20%+ CAGR), with a $60-100B+
anti-obesity-medication TAM by 2030. Novo's Diabetes & Obesity Care is ~94% of sales
(DKK 289.5B
of DKK 309.1B).
Semaglutide is patent-protected, capacity-constrained, and clinically entrenched. The theme is real,
durable, and growing well above GDP.
Clean Duopoly -- But the #2 Losing Share
Structurally Weaker of Two Leaders
Lilly's tirzepatide is clinically superior on weight loss and has overtaken Novo in GLP-1 share both
in the US (Lilly ~60% / Novo ~39%) and ex-US (Lilly ~53% / Novo ~47%). So while the theme is
exploding and the structure is a clean oligopoly, Novo is the #2 and losing share in the
highest-growth segment. Novo is also cutting price (cash/CVS channels, Wegovy pill access) to defend
volume -- pricing power is eroding at the margin.
Insulin & Rare Disease -- Mature Tail
Near-Utility Insulin + Fragmented Rare Disease
Insulin (~45% global share) is a mature, low-growth near-utility franchise. Rare disease (~6% of
sales, DKK 19.6B)
sits in a fragmented market (Roche, Pfizer, Takeda, Alnylam, BioMarin) where Novo is not dominant.
Neither is a needle-mover against the obesity theme.
Segment Exposure -- Share / TAM / Theme
| Segment | % of Rev | Market Share | Theme Growth |
|---|---|---|---|
| Obesity care (Wegovy/CagriSema) | ~27% | ~40% US / ~47% ex-US GLP-1 obesity (duopoly with Lilly, ~98% together) | Very high (~20%+ CAGR) |
| GLP-1 diabetes (Ozempic/Rybelsus) | ~36% | ~46% GLP-1 diabetes value share | High but decelerating |
| Insulin & other diabetes | ~30% | ~45% global insulin; ~30% total diabetes value share | Flat / declining |
| Rare disease | ~6% | Single-digit / not dominant (1 of 5+ players) | Moderate (~6%) |
Oligopoly Gate
| Criterion | Result |
|---|---|
| Novo share in core GLP-1 / diabetes / insulin | 30-47% |
| Any segment >30% share? | Yes (multiple) |
| Key competitor | Eli Lilly (the other duopolist) |
| Gate result | PASS |
7/10 — Best-in-class thematic exposure:
a genuine duopoly inside the strongest growth theme in healthcare, with multiple >30% share positions
and high replacement barriers (semaglutide is patent-protected, capacity-constrained, and clinically
entrenched -- no 12-month customer substitution). The clean oligopoly plus a huge growing TAM would
argue for an 8-9. But Novo is the structurally weaker of the two leaders, having ceded GLP-1 leadership
to Lilly on both sides of the Atlantic and now defending with price cuts. Per "don't settle for the #2
in a market," that pulls it to a 7 -- strong theme, durable but eroding position, not the leader.
Data sourced from Daloopa (company_id: 50204) and public market-share/TAM sources (CNBC, Morningstar, IQVIA, Evaluate, GxP News, Future Market Insights, GlobeNewswire).